The results of TIMER 2.0 analysis illustrate that Bcl2 is overexpressed in several cancers, including HNSC, BC, LUSC, KIRC, LGG, THCA, SARC, LUAD, and UCEC (Fig. 1). Also, the bc-GenEXMiner was assessed to analyse the link between Bcl2 and clinicopathological traits in BC individuals. Here, BCL2 is linked to cancer.